Polymorphisms in TP53 (rs1042522), p16 (rs11515 and rs3088440) and NQO1 (rs1800566) genes in Thai cervical cancer patients with HPV 16 infection

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 1, 2013, Pages 341-346

  Chansaenroj, Jira ^a   Theamboonlers, Apiradee ^a   Junyangdikul, Pairoj ^b   Swangvaree, Sukumarn ^b   Karalak, Anant ^b   Chinchai, Teeraporn ^b   Poovorawan, Yong ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b SRINAKHARINWIROT UNIVERSITY   (Thailand)

Author keywords

Human papillomavirus; NQO1; p16; Single nucleotide polymorphisms; TP53

Indexed keywords

EID: 84877131932     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.1.341     Document Type: Article

References (39)

1. Brooks CL, Gu W (2006). p53 ubiquitination: Mdm2 and beyond. Mol Cell, 21, 307-15.
2. Chansaenroj J, Lurchachaiwong W, Termrungruanglert W, et al (2010). Prevalence and genotypes of human papillomavirus among Thai women. Asian Pac J Cancer Prev, 11, 117-22.
3. Chattopadhyay K (2011). A comprehensive review on host genetic susceptibility to human papillomavirus infection and progression to cervical cancer. Indian J Hum Genet, 17, 132-44.
4. Chansaenroj J, Theamboonlers A, Junyangdikul P, et al (2012). Whole genome analysis of human papillomavirus type 16 multiple infection in cervical cancer patients. Asian Pac J Cancer Prev, 13, 599-606.
5. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M (2006). NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15, 979-87.
6. Eltahir HA, Elhassan AM, Ibrahim ME (2012). Contribution of retinoblastoma LOH and the p53 Arg/Pro polymorphism to cervical cancer. Mol Med Report, 6, 473-6.
7. Geddert H, Kiel S, Zotz RB, et al (2005). Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol, 131, 803-8.
8. Hemminki K, Dong C, Vaittinen P (1999). Familial risks in cervical cancer: Is there a hereditary component? Int J Cancer, 82, 775-81.
9. Hu X, Zhang Z, Ma D, et al (2010). TP53, MDM2, NQO1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev, 19, 755-61.
10. Jee SH, Won SY, Yun JE, et al (2004). Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet, 85, 301-8.
11. Kelsey KT, Ross D, Traver RD, et al (1997). Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anticancer chemotherapy. Br J Cancer, 76, 852-54.
12. Kohaar I, Thakur N, Salhan S, et al (2007). TNFalpha-308G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cell Oncol, 29, 249-56.
13. Koushik A, Platt RW, Franco EL (2004). p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev, 13, 11-22.
14. Koshiol J, Lindsay L, Pimenta JM, et al (2008). Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol, 168, 123-37.
15. Koshiol J, Hildesheim A, Gonzalez P, et al (2009). Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited. Cancer Epidemiol Biomarkers Prev, 18, 1631-7.
16. Lafuente MJ, Casterad X, Trias M, et al (2000). NAD(P) H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis, 21, 1813-9.
17. Makni H, Franco EL, Kaiano J, et al (2000). P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer, 87, 528-33.
18. Magnusson PK, Sparen P, Gyllensten UB (1999). Genetic link to cervical tumours. Nature, 400, 29-30.
19. Meek DW (2009). Tumor suppression by p53: a role for the DNA damage response? Nat Rev Cancer, 9, 714-23.
20. Narisawa-Saito M, Kiyono T (2007). Basic mechanisms of highrisk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci, 98, 1505-11.
21. Niwa Y, Hirose K, Nakanishi T, et al (2005). Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. Gynecol Oncol, 96, 423-9.
22. Ojeda JM, Ampuero S, Rojas P, et al (2003). p53 codon 72 polymorphism and risk of cervical cancer. Biol Res, 36, 279-83.
23. Oliveira S, Sousa H, Santos AM, et al (2008). The p53 R72P polymorphism does not influence cervical cancer development in a Portuguese population: a study in exfoliated cervical cells. J Med Virol, 80, 24-9.
24. Piña-Sánchez P, Hernández-Hernández DM, Taja-Chayeb L, et al (2011). Polymorphism in exon 4 of TP53 gene associated to HPV 16 and 18 in Mexican women with cervical cancer. Med Oncol, 28, 1507-13.
25. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH (1995). Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics, 5, 199-206.
26. Rogler A, Rogenhofer M, Borchardt A, et al (2011). P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: association between disease onset and proline genotype. Pathobiology, 78, 193-200.
27. Sauroja I, Smeds J, Vlaykova T, et al (2000). Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer, 28, 404-4.
28. Schulz WA, Krummeck A, Rösinger I, et al (1997). Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 7, 235-9.
29. Siegel D, McGuinness SM, Winski SL, Ross D (1999). Genotypephenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics, 9, 113-21.
30. Sousa H, Santos AM, Pinto D, Medeiros R (2011). Is there a biological plausibility for p53 codon 72 polymorphism influence on cervical cancer development? Acta Med Port, 24, 127-34.
31. Sousa H, Santos AM, Pinto D, Medeiros R (2007). Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int J Mol Med, 20, 731-41.
32. Storey A, Thomas M, Kalita A, et al (1998). Role of a p53 polymorphism in the development of human papillomavirusassociated cancer. Nature, 393, 229-34.
33. Thakur N, Hussain S, Nasare V, et al (2012). Association analysis of p16 (CDKN2A) and RB1 polymorphisms with susceptibility to cervical cancer in Indian population. Mol Biol Rep, 39, 407-14.
34. Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19, 1092-100.
35. Thurow HS, Haack R, Hartwig FP, et al (2011). TP53 gene polymorphism: importance to cancer, ethnicity and birth weight in a Brazilian cohort. J Biosci, 36, 823-31.
36. Tsvetkov P, Reuven N, Shaul Y (2010). Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ, 17, 103-8.
37. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.
38. Yan L, Na W, Shan K, et al (2008). p16 (CDKN2) gene polymorphism: association with histologic subtypes of epithelial ovarian cancer in China. Int J Gynecol Cancer, 18, 30-5.
39. Zheng Y, Shen H, Sturgis EM, et al (2002). Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Epidemiol Biomarkers Prev, 11, 640-5.